Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 81Terminated 19Withdrawn 9Active not recruiting 5Recruiting 3Unknown 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 41Lymphoma, B-Cell, Marginal Zone 22Lymphoma, Mantle-Cell 20Lymphoma, Follicular 18Lymphoma 17Lymphoma, Non-Hodgkin 15Leukemia, Lymphocytic, Chronic, B-Cell 12Lymphoma, B-Cell 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Recurrence 8Burkitt Lymphoma 8Waldenstrom Macroglobulinemia 7Neoplasms 6Leukemia, Hairy Cell 4Leukemia, B-Cell 3Leukemia 3Hematologic Neoplasms 3beta-Thalassemia 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm, Residual 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Heart Failure 2Epstein-Barr Virus Infections 2Dendritic Cell Sarcoma, Interdigitating 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Anemia, Refractory, with Excess of Blasts 2Thalassemia 1Sjogren's Syndrome 1

Interventions

venetoclax 22Cyclophosphamide 14Cytarabine 12Azacitidine 8fludarabine 7Daunorubicin 5ruxolitinib 4revumenib 4Trimethoprim, Sulfamethoxazole Drug Combination 4Dexamethasone 4quizartinib 3pirtobrutinib 3gamma-Globulins 3fludarabine phosphate 3blinatumomab 3Tacrolimus 3Rituximab 3Palliative Care 3Granulocyte Colony-Stimulating Factor 3Decitabine 3Ciprofloxacin 3Blood Specimen Collection 3zanubrutinib 2pembrolizumab 2ibrutinib 2aldesleukin 2acalabrutinib 2Watchful Waiting 2Mycophenolic Acid 2Melphalan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Leukemia × Rituximab × Clear all
NCT05645718 2026-05-19

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
27 enrolled
Other hematologic neoplasm

Leukemia

NCT07294677 2026-03-04

CAVALRY

University of Chicago

Phase 1/2 Recruiting
104 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT06644183 2026-02-11

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
64 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡